OClawVPS.com
Aleva Neurotherapeutics SA
Edit

Aleva Neurotherapeutics SA

https://www.aleva-neuro.com/
Last activity: 05.08.2024
Active
Categories: CommerceEmployeeEquipmentHardwareIndustryMedTechPlatformProductionSalesTechnology
ALEVA is 👉THE COMPANY THAT INTRODUCED Directional Deep Brain Stimulation in Neuromodulation treatments and our clinically proven technology has set the industry standard for directional leads*

Today we are 👉A SOLID COMPANY that following directSTIM™'s CE marking have started our commercial journey by partnering with the most important neurological clinics in Germany, with the goal to soon reach the most relevant European markets.

We understand that if we want to help OUR CUSTOMERS, overcome their challenges, we need to 👉COMBINE SPECIALISATION with the 👉COMMITMENT TO BE RESPONSIVE to the everyday new challenges they experience. This is the attitude you will find in every ALEVA employee and sales representative who will be in contact with you.

We are the 👉ONLY EUROPEAN COMPANY that designs, manufactures, and commercialises DBS devices for the treatment of Parkinson’s disease and essential tremor.
Our production and R&D headquarters based in Switzerland complies to the highest quality standard for the highest safety of patients worldwide.


Our A VISIONARY PROJECT SUSTAINED BY SOLID FOUNDATIONS:
👉a new group of investors that will sustain the completion of OUR PROJECT
👉a reinforced executive team who is complementing the existing successful group to partner with Neurosurgeons and Neurologists in the effective deployment of our Vision.

*May 28, 2014 http://doi.org/10.1093/brain/awu102.
Followers
2.98K
Mentions
36
Location: Switzerland, Vaud, Lausanne
Employees: 51-200
Total raised: $57.24M
Founded date: 2013

Investors 3

Funding Rounds 5

DateSeriesAmountInvestors
17.12.2019Series E$8.14M-
03.10.2017Series D$13M-
27.05.2016Series C$18M-
10.04.2012Series B$4.36M-
30.08.2011Series A$13.75M-

Mentions in press and media 36

DateTitleDescription
20.09.2022CE-Mark for Aleva’s Deep Brain Stimulation
02.06.2022Sparks IPO Academy completes first edition with 13 companies
28.02.2022Aleva receives FDA approval to start US Study
09.07.2021Successful collaboration between Aleva Neurotherapeutics and DIXI MedicalAdept Neuro has exclusive intellectual property rights of Aleva Neurotherapeutics in the fields of epilepsy. DIXI Medical ensures the exclusive production and distribution of the Adept Neuro’s products, while DIXI Holding will finance the j...
22.06.2021Aleva’s first Deep Brain Stimulation System implantedDeep brain stimulation (DBS) is approved worldwide for the treatment of Parkinson’s disease (PD), essential tremor, dystonia, obsessive-compulsive disorder (OCD), and epilepsy. The approach relies on the delivery of mild electrical pulses t...
22.06.2021Aleva’s first Deep Brain Stimulation System implanted
03.08.2020Three companies a step away from winning the Swiss Medtech AwardEvery year, the Swiss Medtech Award honours the most outstanding medical technologies in Switzerland. From its shortlist of eleven start-ups, the selection committee has nominated three companies that will have the opportunity to present th...
03.08.2020Three companies a step away from winning the Swiss Medtech Award
25.06.2020Swiss Medtech Award presents the shortlistThe Swiss Medtech Award recognises the most outstanding medical technologies in Switzerland. The jury has selected seven companies that will further compete for one of three spots of the final round and to get the chance to present their id...
25.06.2020Swiss Medtech Award presents the shortlist
Show more

Reviews 0

Sign up to leave a review

Sign up Log In